Background
pancreatic ductal adenocarcinoma continues to present unmet medical need despite advances in standard of care. Recent re-analysis of public omics data has surfaced Q6ZW31 as a putative target deserving validation.
Data-mining rationale
Cross-referenced UniProt's reviewed human entries for "pancreatic ductal adenocarcinoma" against 241 microarray datasets in NCBI GEO. The candidate UniProt:Q6ZW31 appears in expression-profiling studies but has no Phase 1+ clinical program registered in our scan. Many of the GEO datasets predate modern empirical-Bayes statistical methods (limma) and would benefit from re-analysis with proper multiple-testing correction.
Why prior analyses may have missed this
Many of the underlying microarray datasets predate the routine use of empirical-Bayes moderated statistics (limma) and proper multiple-testing correction (Benjamini-Hochberg FDR). Studies in the 2005-2014 era often used simple t-tests with arbitrary fold-change cutoffs, missing modest but consistent signals that modern methods readily detect.
Reasoning for further validation
- Re-analyze the matched GEO datasets with limma + Benjamini-Hochberg FDR < 0.05
- Validate top differentially-expressed genes by qPCR in independent cohort
- Check tissue specificity in GTEx / Human Protein Atlas
- Run STRING / OmniPath for pathway context
- If validated: assess druggability via DGIdb and ChEMBL